Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04879017 · ClinicalTrials.gov registry record · Phase 1
FHD-286 in Subjects With Metastatic Uveal Melanoma
A Phase 1 study, sponsored by Foghorn Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 76
- Enrollment target
NCT04879017 is a Phase 1 study that was terminated before completion, run by Foghorn Therapeutics. The registered enrollment target is 76 participants.
The verdict
NCT04879017, a Phase 1 study, was terminated before completion, sponsored by Foghorn Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 76 participants
- Enrollment target
Study Summary
This Phase 1, multicenter, open-label, dose escalation and expansion study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 oral monotherapy in subjects with metastatic Uveal Melanoma (UM).
Interventions
- DRUG FHD-286
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2021-05-11 |
| Est. Completion | 2023-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04879017
The ClinicalTrials.gov registry entry for NCT04879017 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Foghorn Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FHD-286 is the first listed.
NCT04879017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04879017 about?
NCT04879017 is a clinical study titled "FHD-286 in Subjects With Metastatic Uveal Melanoma". This Phase 1, multicenter, open-label, dose escalation and expansion study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of FHD-286 oral monotherapy in subjects with metastatic Uveal Melanoma (UM).
What is the current status of trial NCT04879017?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 76 participants. The study started on 2021-05-11. Estimated completion is 2023-11-30.
What interventions are being tested in trial NCT04879017?
The interventions under investigation include: FHD-286 (DRUG).
Who is sponsoring clinical trial NCT04879017?
This trial is sponsored by Foghorn Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.